0
Other Articles |

SULFAPYRIDINE IN THE TREATMENT OF PNEUMONIA IN INFANCY AND CHILDHOOD

ARMINE T. WILSON, M.D.; ARTHUR H. SPREEN, M.D.; MERLIN L. COOPER, M.D.; FRANK E. STEVENSON, M.D.; GLENN E. CULLEN, Ph.D.; A. GRAEME MITCHELL, M.D.
JAMA. 1939;112(15):1435-1439. doi:10.1001/jama.1939.02800150007002.
Text Size: A A A
Published online

The results of the use of 2-(para-aminobenzenesulfonamido) pyridine, officially known as sulfapyridine, in animal experiments and the favorable effects obtained with it in the treatment of pneumonic infections in human beings warrant a trial of this drug with infants and children under carefully controlled conditions. Furthermore, whenever possible the results of such a study should be subjected to statistical analysis. For this purpose we have employed the methods of Fisher1 because they appeared to be the most appropriate for the analysis of a small series.2 Both the value and the possible harmful effects of sulfapyridine must be determined as soon as possible so that physicians may know how widely it should be used. No attempt will be made to review the literature on this subject, since adequate reviews are available.3

In a study of any treatment of pneumonia in children the low case fatality rate makes it

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs